Xtandi, Astellas’ roughly $6 billion prostate cancer juggernaut by annual sales, is set to lose U.S. patent protection in ...

The FDA has told the makers of six flu vaccines that they need to add a notification to the label of their shots, warning of ...

This time, Tecvayli excelled as a solo agent, reducing the risk of disease progression or death by 71% over standard of care ...

The regulator’s Office of Prescription Drug Promotion (OPDP) has already sent out two letters alleging “false or misleading” ...

Hologic has drafted professional basketball player Erica Wheeler to raise awareness of cervical cancer screening, putting the ...

The move comes in response to increasing delivery demands for GLP-1s, plus broader conversations about pharmaceutical ...

In fact, the price of such vouchers has been climbing steadily in recent months, according to public disclosures surrounding ...

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

As part of its mission to make a dent in the sizable presbyopia market, Lenz Therapeutics has scoped out a star-studded ...

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...

Though far from the first large drugmaker to strike a pricing deal with the Trump administration, AbbVie’s new accord is ...